摘要
目的 :研究国产rhG CSF(吉粒芬 ,杭州九源基因公司生产 )在浆细胞病患者自体外周血干细胞移植中对造血干细胞动员以及回输后造血重建的有效性和安全性。方法 :对 3例多发性骨髓瘤患者和 1例Waldenstrom巨球蛋白血症患者实施自体造血干细胞移植。采用化疗联合吉粒芬 5 μg (kg·d) ,皮下注射。在干细胞回输后第 2天开始使用吉粒芬 5 μg (kg·d) ,直至造血重建。 结果 :在使用吉粒芬 6 .5± 1.7天动员过程后 ,经过 1— 2次的采集 ,获得 (2 .38± 0 .36 )× 10 6 kg的CD34 +细胞。在回输后注射吉粒芬 11.5± 2 .1天后中性粒细胞绝对计数 (ANC)>5 0 0 μl,血小板计数 (PLT) >2 0× 10 6 L ,造血重建。 4例患者均未出现骨痛、发热及肝肾功能受损等毒副作用。结论 :吉粒芬在浆细胞病患者自体外周血干细胞移植中是安全、有效的。因而将明显降低移植的费用。
Purpose:To investigate the efficacy and safety of rhG-CSF in mobilization of stem cells and reconstitution of hematopoiesis of patients with plasma cell diseases in autologus peripheral blood stem cell transplantation (auto-PBSCT). Methods:Four cases were accepted for Auto-PBSCT including three patients with multiple myeloma(MM) and one with Waldenstrom Syndrome. High dose chemotherapy combined with 5 μg/(kg·d) of rhG-CSF was given in s.c for mobilization, and 5 μg/(kg·d) of rhG-CSF was given from the next day after infusion until reconstitution of hematopoiesis. Results:After (6.5±1.7) days of injection with rhG-CSF, (2.38±0.36)×10 6/kg CD34 + cells were harvested through 1-2 collections. (11.5±2.08) days later after infusion, the hematopoietic function had recovered, ANC>500/μl and PLT>20×10 6/L were observed in the blood. No patients presented bone pain, fever, abnormal function of liver and kidney, and so on. Conclusions:Our results indicated that rhG-CSF is efficacious and safe in auto-PBSCT for patients with plasma cell diseases. Therefore, the expense of hospitalization would be reduced significantly.
出处
《中国癌症杂志》
CAS
CSCD
2001年第6期522-524,共3页
China Oncology
